

Study Published in *Stroke* Offers Promise to Severe Stroke Victims

Active ingredient of Remedy Pharmaceutical's drug, RP-1127, shown superior to decompressive surgery in treating malignant stroke

New York, NY, USA - March 31, 2010 – Remedy Pharmaceuticals, Inc. today announced that an important preclinical study validating the use of RP-1127 in treating malignant infarction has been published in the prestigious journal, *Stroke*.

The study titled “Glibenclamide is superior to decompressive craniectomy in a rat model of malignant stroke” clearly shows that in a rat model of severe ischemia/reperfusion, with reperfusion and treatment beginning six hours after onset of stroke, the active ingredient of RP-1127 is as effective as decompressive surgery in preventing death from malignant cerebral edema but is superior to decompressive surgery in preserving neurologic function and the integrity of watershed cortex and deep white brain matter.

Malignant stroke is the syndrome of a large stroke causing progressive edema and tissue swelling that compromises arterial inflow to surrounding tissues, culminating in further ischemic damage, enlargement of the infarct, herniation, and death. There are currently no approved pharmaceutical therapies for malignant infarction. Without therapy, up to 80% of these patients will die from brain herniation or require decompressive surgery to relieve brain swelling.

Details of the publication follow:

Glibenclamide is superior to decompressive craniectomy in a rat model of malignant stroke. Simard JM, Tsymbalyuk N, Tsymbalyuk O, Ivanova S, Yurovsky V, Gerzanich V. *Stroke*. 2010 Mar;41(3):531-7.

About RP-1127

Remedy's lead drug candidate, RP-1127, is a high affinity, well tolerated inhibitor of NC_{Ca}-ATP channels, which are key upstream mediators of the development of brain swelling (edema) and hemorrhage following ischemic and traumatic injury.

About Remedy Pharmaceuticals

Remedy Pharmaceuticals, Inc. is a clinical stage pharmaceutical company focused on the development and commercialization of small molecule drugs for acute central nervous system disorders including stroke, traumatic brain injury, and spinal cord injury.

For more information, email: info@remedypharmaceuticals.com